AN2 Therapeutics Inc (ANTX)
1.34
+0.11
(+8.94%)
USD |
NASDAQ |
Nov 22, 16:00
1.34
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Enterprise Value: -53.39M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | -53.39M |
| November 21, 2024 | -56.68M |
| November 20, 2024 | -54.58M |
| November 19, 2024 | -61.75M |
| November 18, 2024 | -63.55M |
| November 15, 2024 | -63.55M |
| November 14, 2024 | -63.55M |
| November 13, 2024 | -63.25M |
| November 12, 2024 | -61.75M |
| November 11, 2024 | -60.86M |
| November 08, 2024 | -60.56M |
| November 07, 2024 | -60.56M |
| November 06, 2024 | -60.56M |
| November 05, 2024 | -60.87M |
| November 04, 2024 | -61.17M |
| November 01, 2024 | -61.17M |
| October 31, 2024 | -61.17M |
| October 30, 2024 | -60.87M |
| October 29, 2024 | -60.27M |
| October 28, 2024 | -60.57M |
| October 25, 2024 | -61.47M |
| October 24, 2024 | -61.47M |
| October 23, 2024 | -61.17M |
| October 22, 2024 | -61.17M |
| October 21, 2024 | -61.17M |
| Date | Value |
|---|---|
| October 18, 2024 | -62.06M |
| October 17, 2024 | -62.66M |
| October 16, 2024 | -61.77M |
| October 15, 2024 | -62.06M |
| October 14, 2024 | -62.66M |
| October 11, 2024 | -62.06M |
| October 10, 2024 | -62.36M |
| October 09, 2024 | -62.36M |
| October 08, 2024 | -62.36M |
| October 07, 2024 | -62.36M |
| October 04, 2024 | -61.47M |
| October 03, 2024 | -62.36M |
| October 02, 2024 | -62.06M |
| October 01, 2024 | -62.06M |
| September 30, 2024 | -61.47M |
| September 27, 2024 | -72.91M |
| September 26, 2024 | -73.06M |
| September 25, 2024 | -73.21M |
| September 24, 2024 | -73.50M |
| September 23, 2024 | -73.50M |
| September 20, 2024 | -73.21M |
| September 19, 2024 | -72.31M |
| September 18, 2024 | -72.91M |
| September 17, 2024 | -72.91M |
| September 16, 2024 | -73.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-75.29M
Minimum
Aug 16 2024
533.04M
Maximum
Jan 09 2024
117.45M
Average
80.70M
Median
Mar 09 2023
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.91B |
| Arbutus Biopharma Corp | 537.32M |
| GlycoMimetics Inc | 6.037M |
| FibroGen Inc | 23.59M |
| Cidara Therapeutics Inc | 16.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.75M |
| Total Expenses (Quarterly) | 11.77M |
| EPS Diluted (Quarterly) | -0.43 |
| Earnings Yield | -152.2% |